Cohort study2021Open access

Association of Docosahexaenoic Acid and Arachidonic Acid Serum Levels With Retinopathy of Prematurity in Preterm Infants

Hellström A, Pivodic A, Gränse L, Lundgren P, Sjöbom U, Nilsson AK, Söderling H, Hård AL, Smith LEH, Löfqvist CA

JAMA network open · 55 citations

How it was studied

Design
Cohort study (indexed by PubMed)
Studied in
People
Main outcome
Clinical events such as disease or death

Who paid for it

Funding
Independent funding
Government
National Eye Institute
Government
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Government
NICHD NIH HHS
Government
NEI NIH HHS
Grants
Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50‐HD105351); National Eye Institute (R01EY017017); Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD090255); National Eye Institute (R01 EY030904)

Based on 4 listed funder(s).

Publication

Published
2021-10-14 · JAMA Netw Open · vol. 4 · issue 10 · p. e2128771
Publisher
American Medical Association
Cited
63 citations · more than 97% of similar papers · 6.1× the field average
Impact
Top 10% most cited in its field
References
46 works
Access
Open access (journal) · CC-BY
Research areas
Retinopathy of Prematurity Studies · Fatty Acid Research and Health · Neonatal Respiratory Health Research
Keywords
Retinopathy of prematurity, Docosahexaenoic acid, Arachidonic acid, Association (psychology), Medicine, Internal medicine, Gestational age, Biology, Psychology, Biochemistry, Fatty acid, Pregnancy, Polyunsaturated fatty acid, Genetics
MeSH
humans, retinopathy of prematurity, docosahexaenoic acids, arachidonic acid, logistic models, odds ratio, cohort studies, gestational age, infant, infant, newborn, infant, premature, sweden, female, male

10 authors

From SE, US

  • Ann HellströmUniversity of Gothenburg
  • Aldina PivodicUniversity of Gothenburg
  • Lotta GränseLund University; Skåne University Hospital
  • Pia LundgrenÖrebro University; University of Gothenburg
  • Ulrika SjöbomUniversity of Gothenburg
  • Anders NilssonUniversity of Gothenburg

Abstract

Importance

Supplementing preterm infants with long-chain polyunsaturated fatty acids (LC-PUFA) has been inconsistent in reducing the severity and incidence of retinopathy of prematurity (ROP). Furthermore, few studies have measured the long-term serum lipid levels after supplementation.

Objective

To assess whether ROP severity is associated with serum levels of LC-PUFA, especially docosahexaenoic acid (DHA) and arachidonic acid (AA), during the first 28 postnatal days.

Design, setting, and participants

This cohort study analyzed the Mega Donna Mega study, a randomized clinical trial that provided enteral fatty acid supplementation at 3 neonatal intensive care units in Sweden. Infants included in this cohort study were born at a gestational age of less than 28 weeks between December 20, 2016, and August 6, 2019.

Main outcomes and measures

Severity of ROP was classified as no ROP, mild or moderate ROP (stage 1-2), or severe ROP (stage 3 and type 1). Serum phospholipid fatty acids were measured through gas chromatography-mass spectrometry. Ordinal logistic regression, with a description of unadjusted odds ratio (OR) as well as gestational age- and birth weight-adjusted ORs and 95% CIs, was used. Areas under the curve were used to calculate mean daily levels of fatty acids during postnatal days 1 to 28. Blood samples were obtained at the postnatal ages of 1, 3, 7, 14, and 28 days.

Results

A total of 175 infants were included in analysis. Of these infants, 99 were boys (56.6%); the median (IQR) gestational age was 25 weeks 5 days (24 weeks 3 days to 26 weeks 6 days), and the median (IQR) birth weight was 785 (650-945) grams. A higher DHA proportion was seen in infants with no ROP compared with those with mild or moderate ROP or severe ROP (OR per 0.5-molar percentage increase, 0.49 [95% CI, 0.36-0.68]; gestational age- and birth weight-adjusted OR, 0.66 [95% CI, 0.46-0.93]). The corresponding adjusted OR for AA levels per 1-molar percentage increase was 0.83 (95% CI, 0.66-1.05). The association between DHA levels and ROP severity appeared only in infants with sufficient AA levels, suggesting that a mean daily minimum level of 7.8 to 8.3 molar percentage of AA was necessary for a detectable association between DHA level and less severe ROP.

Conclusions and relevance

This cohort study found that higher mean daily serum levels of DHA during the first 28 postnatal days were associated with less severe ROP even after adjustment for known risk factors, but only in infants with sufficiently high AA levels. Further studies are needed to identify LC-PUFA supplementation strategies that may prevent ROP and other morbidities.

Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).

Community trust

Loading…

How much do you trust this study's findings?

0 · not at all10 · completely

Comments

Sign in to rate, comment on or flag this study.Sign in

Something wrong here?

Flag this study if its information, labels or funding look wrong. An editor reviews every flag.

Sign in to rate, comment on or flag this study.Sign in

Educational information about published research. Not medical advice, and not a recommendation to start or stop anything.